Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:01:42.717Z.
Calculation as of: 2026-10-06T18:01:42.717Z.
Quote observation: 2026-10-06T17:59:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c88c4f39e0f2b8ce509c05ad310ef4a925915372bb385716b1b31bbca6f45484
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$29.81M
PS Ratio
185.91
TTM Avg
248.61
3Y Avg
248.61
5Y Avg
248.61
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | $29.52M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.60M | 118.22 | 48.99 | 48.99 | 48.99 |
| GridAI Technologies Corp. (GRDX)vs › | $29.81M | 185.91 | 248.61 | 248.61 | 248.61 |
| OneMedNet Corporation (ONMD)vs › | $29.19M | 20.05 | 65.83 | 42.42 | 57.23 |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $30.05M | N/A | N/A | N/A | N/A |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $28.86M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $30.33M | N/A | 74.19 | 53.76 | 254.70 |
| CervoMed Inc. (CRVO)vs › | $30.41M | 94.29 | 131.68 | 131.68 | 131.68 |
| MDxHealth S.A. (MDXH)vs › | $30.61M | N/A | N/A | N/A | N/A |
| SCYNEXIS, Inc. (SCYX)vs › | $30.69M | 1.60 | 5.95 | 5.97 | 11.91 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-23 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
